| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Protein aggregation occurs when 1.5 mM chlorpyrifos-oxon (CPO) is applied to tubulin. Nonetheless, cross-linked trimers between chlorpyrifos and oxon are visible even at 1.5 μM. Chlorpyrifos-oxon facilitates tubulin monomers' isopeptide bond cross-linking to form multimers[2]. Neurite outgrowth was hindered in PC12 cells cultured for 24 hours when exposed to chlorpyrifos at a dosage 10-fold lower than that which inhibits AChE activity (3.0 μM), but neurite outgrowth is inhibited at 1.0 nM by chlorpyrifos-oxon[3].
|
|---|---|
| ln Vivo |
Human liver microsomes quickly detoxify chlorpyrifos-oxon (CPO) by glutathione-S-transferase and CYP-dependent deethylation and dearylation. Furthermore, Chlorpyrifos-oxon may be quickly degraded or scavenged in the liver by interactions with A-esterases like paraoxonase 1 (PON 1) or B-esterases such carboxylesterase and butyrylcholinesterase (BChE)[1]. Following treatment with Chlorpyrifos-oxon (3 mg/kg, ip; once); wild-type mice, the microtubule dimensions of the treated mice resemble those of the control mice by almost 60%. Mice exposed to chlorpyrifos-oxon had microtubules with aberrant structures and covalently changed amino acids, which may indicate a disruption in microtubule function[4].
|
| References |
[1]. Florian Eyer, et al. Extreme variability in the formation of chlorpyrifos oxon (CPO) in patients poisoned by chlorpyrifos (CPF). Biochem Pharmacol. 2009 Sep 1;78(5):531-7.
[2]. Lawrence M Schopfer, et al. Chlorpyrifos oxon promotes tubulin aggregation via isopeptide cross-linking between diethoxyphospho-Lys and Glu or Asp: Implications for neurotoxicity. J Biol Chem. 2018 Aug 31;293(35):13566-13577. [3]. Jie Gao, et al. Chlorpyrifos and chlorpyrifos oxon impair the transport of membrane bound organelles in rat cortical axons. Neurotoxicology. 2017 Sep;62:111-123. [4]. Wei Jiang, et al. Mice treated with chlorpyrifos or chlorpyrifos oxon have organophosphorylated tubulin in the brain and disrupted microtubule structures, suggesting a role for tubulin in neurotoxicity associated with exposure to organophosphorus agents. |
| Molecular Formula |
C9H11CL3NO4P
|
|---|---|
| Molecular Weight |
334.52
|
| CAS # |
5598-15-2
|
| Related CAS # |
Chlorpyrifos-oxon-d10;1794779-85-3
|
| SMILES |
CCOP(OC1=NC(Cl)=C(Cl)C=C1Cl)(=O)OCC
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (298.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.47 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.47 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9894 mL | 14.9468 mL | 29.8936 mL | |
| 5 mM | 0.5979 mL | 2.9894 mL | 5.9787 mL | |
| 10 mM | 0.2989 mL | 1.4947 mL | 2.9894 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
